CN120916775A - 抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂 - Google Patents
抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂Info
- Publication number
- CN120916775A CN120916775A CN202480015575.2A CN202480015575A CN120916775A CN 120916775 A CN120916775 A CN 120916775A CN 202480015575 A CN202480015575 A CN 202480015575A CN 120916775 A CN120916775 A CN 120916775A
- Authority
- CN
- China
- Prior art keywords
- piv
- cancer
- ccl19
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18733—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18741—Use of virus, viral particle or viral elements as a vector
- C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363449055P | 2023-03-01 | 2023-03-01 | |
| US63/449,055 | 2023-03-01 | ||
| PCT/JP2024/007475 WO2024181525A1 (ja) | 2023-03-01 | 2024-02-29 | 抗がん剤、がん治療用医薬組成物、キット、及び活性化剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120916775A true CN120916775A (zh) | 2025-11-07 |
Family
ID=92589933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202480015575.2A Pending CN120916775A (zh) | 2023-03-01 | 2024-02-29 | 抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4674421A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024181525A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN120916775A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024181525A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1213004A (zh) * | 1997-09-29 | 1999-04-07 | 成都拜奥生物技术研究所 | 重组白细胞介素-2腺病毒载体及产生方法 |
| JP5801202B2 (ja) | 2009-09-29 | 2015-10-28 | 学校法人慶應義塾 | 抗腫瘍剤およびそのスクリーニング方法 |
| JP5807917B2 (ja) | 2011-02-08 | 2015-11-10 | 国立大学法人三重大学 | 遺伝子導入用ウイルスベクターの製造方法 |
| JP6358706B2 (ja) | 2012-12-26 | 2018-07-18 | バイオコモ株式会社 | ヒトパラインフルエンザ2型ウイルスベクターを利用したワクチン |
| AU2017272721B2 (en) * | 2016-05-30 | 2023-03-30 | Astellas Pharma Inc. | Novel genetically engineered vaccinia viruses |
| KR20230100748A (ko) | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| CA3075886A1 (en) * | 2017-10-10 | 2019-04-18 | Yamaguchi University | Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells |
| US20210379129A1 (en) | 2018-10-09 | 2021-12-09 | Biocomo Incorporation | Anticancer agent, pharmaceutical composition for cancer treatment, and kit |
-
2024
- 2024-02-29 JP JP2025503986A patent/JPWO2024181525A1/ja active Pending
- 2024-02-29 CN CN202480015575.2A patent/CN120916775A/zh active Pending
- 2024-02-29 WO PCT/JP2024/007475 patent/WO2024181525A1/ja not_active Ceased
- 2024-02-29 EP EP24764002.2A patent/EP4674421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2024181525A1 (cg-RX-API-DMAC7.html) | 2024-09-06 |
| WO2024181525A1 (ja) | 2024-09-06 |
| EP4674421A1 (en) | 2026-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fallon et al. | The immunocytokine NHS-IL12 as a potential cancer therapeutic | |
| Kirkwood et al. | Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma | |
| Koya et al. | BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy | |
| Tai et al. | Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells | |
| Den Otter et al. | Local therapy of cancer with free IL-2 | |
| JP6656349B2 (ja) | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 | |
| Jinushi et al. | Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines | |
| Colombo et al. | Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy | |
| Cebon et al. | Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma | |
| Huang et al. | Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth | |
| Suzuki et al. | Soluble type II transforming growth factor-β receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity | |
| JP7809324B2 (ja) | sEphB4-HSA融合タンパク質を用いたがんの治療 | |
| CA2962451A1 (en) | Treatment of cancer with immune stimulators | |
| Donovan et al. | Paracrine activin-A signaling promotes melanoma growth and metastasis through immune evasion | |
| Bukowski et al. | Clinical practice guidelines: renal cell carcinoma | |
| CN115232217B (zh) | 一种SynNotch结构及其应用 | |
| ES2313076T3 (es) | Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica. | |
| Apte et al. | Opposing Effects of IL-1α and IL-1β on Malignancy Patterns: Tumor cell-associated IL-Iα potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness | |
| US20210196744A1 (en) | Compositions for cancer therapy and methods | |
| US20240288425A1 (en) | Selection of patients for combination therapy | |
| US20250177505A1 (en) | Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof | |
| EP4674421A1 (en) | Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator | |
| KR102654518B1 (ko) | Lsp1 결핍 t 세포 | |
| Santiesteban | Relieving Immune Suppression in the Melanoma Tumor Microenvironment | |
| US20220062390A1 (en) | Methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |